Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin alfa for anemia in non-myeloid malignancy
NCT00117624Phase 3Completed
- Sponsor
- Amgen
- Start
- Dec 2002
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Phase 3, randomised, double-blind trial of darbepoetin alfa in anemia (2 arms), sponsored by Amgen. Primary endpoint: RBC transfusion during the treatment phase. Started Dec 2002; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00117624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117624.